GeneDx Holdings (WGS) stock calls: who's bullish, who's bearish, and their track records

Who is bullish and who is bearish on WGS?

Consensus: neutral. Every current directional call on WGS points the same way (Z (@ZeeContrarian1) and PSYwolve (@Wolfspiritbln)).

Every logged WGS call

Dates are the post date in US Central time. Prices are closes in the listing currency. Open calls are not marked to market on this page; they are scored 180 days after the post.

The bull case for WGS

• Repeats that GeneDx is worth revisiting after a 16% one-day drop with no news, which he suspects was forced selling. (Z (@ZeeContrarian1), Oct 26, 2026; source)
• GeneDx fell about 40% from ~$105 to ~$65; author still sees the original genetic-testing thesis intact and views the drop as an opportunity. (Z (@ZeeContrarian1), Oct 23, 2026; source)
• Says GeneDx is becoming interesting again at current prices (already a large holder). (Z (@ZeeContrarian1), Oct 22, 2026; source)
• Adds GeneDx exposure (already a large position) via a Nov 20 options structure: long one 50 call, short one 60 put, short three 80 calls, for a $1 net credit, with earnings before expiry. (Z (@ZeeContrarian1), Oct 20, 2026; source)
• Defends his GeneDx add: great companies have had 80% drawdowns, and he knows the story well. (Z (@ZeeContrarian1), Oct 14, 2026; source)
• Raised GeneDx from 2% to 8% of portfolio, calling it oversold after a fall from about $100 to $65. (Z (@ZeeContrarian1), Oct 13, 2026; source)
• After Q2, says reimbursement is already improving and demand remains strong; recovery story intact but will take time. (Z (@ZeeContrarian1), Aug 4, 2026; source)
• After GeneDx's Q1 reimbursement-driven crash, argues SPAC sponsors Casdin and Corvex buying ~$60M of stock signals the core exome/genome business is intact; sees 2.2x EV/revenue vs ~2x that for peers. (Z (@ZeeContrarian1), May 21, 2026; source)

The bear case for WGS

No tracked investor has a current bearish thesis on WGS.

Neutral and watch-list views

• Argues the roughly 29% implied earnings move in the Nov 13 $65 WGS straddle is excessive and would sell it for about a $19 credit, happy to own below $46. (Z (@ZeeContrarian1), Oct 28, 2026; source)
• Reflects that WGS may have run ahead of itself as it moved from $80 toward $100 with reimbursement improvement partly priced in; gives no sell price. (Z (@ZeeContrarian1), Sep 30, 2026; source)
• Argues the Sep 22 WGS drop reflected a CMS reimbursement proposal (Craig-Hallum ~1% revenue impact), not the 19-month-old code-stacking claims. (PSYwolve (@Wolfspiritbln), Sep 23, 2026; source)

Thesis lines are MCAFax summaries in our own words; follow the source link for the author's full post.

In their own words

• @ZeeContrarian1 (Oct 28, 2026): "That seems excessive to me."
• @ZeeContrarian1 (Oct 26, 2026): "A 16% drop in one day with no news makes no sense."
• @ZeeContrarian1 (Oct 23, 2026): "Why the recent 40% decline might be an opportunity."
• @ZeeContrarian1 (Oct 22, 2026): "$WGS is becoming interesting to me again at these prices."
• @ZeeContrarian1 (Oct 20, 2026): "$WGS is a large position in my portfolio, and I'm adding exposure through an interesting options structure expiring November 20, with earnings in between."
• @ZeeContrarian1 (Oct 14, 2026): "I know the $WGS story very well."

Track records of the players calling WGS

See the full market-calls leaderboard for every player's record.

How we score these calls

A call wins when, 180 days after the post, the stock beat the S&P 500 in the direction the investor called (a long must outperform the index, a short must underperform it). Edge is the gap versus the S&P 500 in percentage points. Price at call is the last close known at the time of the post (Yahoo Finance daily bars, split-adjusted, in the listing currency). Track records cover calls from roughly the past year.

Last updated: November 5, 2026

Not investment advice; for research and education.